

Efficacy of continuous zanubrutinib vs fixed-duration venetoclax in combination with obinutuzumab in treatment-naïve CLL: A matching-adjusted indirect comparison

Authors: Keshu Zhou,¹ Talha Munir,² Keri Yang,³ Leyla Mohseninejad,⁴ Sheng Xu,⁵ Pal Rakonczai,⁶ Balazs Dobi,⁶ Rhys Williams,³ Nicolas Martinez-Calle⁷

Affiliations: ¹Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; ²Leeds Teaching Hospitals NHS Trust, Leeds, UK; ³BeOne Medicines Ltd, San Carlos, CA, USA; ⁴BeOne Medicines Ltd, Schiphol, the Netherlands; ⁵BeOne Medicines Ltd, Shanghai, China; ⁶Evidera, London, UK; ⁷Nottingham University Hospitals NHS Trust, Nottingham, UK

ABSTRACT

Objectives: The efficacy of continuous zanubrutinib has been evaluated in the SEQUOIA study (NCT03336333) in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), while the combination of fixed-duration venetoclax + obinutuzumab (VenO) has been evaluated in CLL14 (NCT02242942). In the absence of head-to-head clinical trials comparing zanubrutinib and VenO, an unanchored matching-adjusted indirect comparison (MAIC) was conducted between zanubrutinib (SEQUOIA) and VenO (CLL14).

Methods: The unanchored MAIC was conducted using study data with similar median follow-up periods (SEQUOIA, 62.67 months; CLL14, 65.4 months). Individual patient data (IPD) of zanubrutinib patients in SEQUOIA were reweighted to match the key population characteristics of VenO patients in CLL14 to perform an unanchored MAIC, given the lack of common control arms between SEQUOIA and CLL14. Matching adjustments for age, sex, ECOG performance status, CLL/SLL patient proportion, disease stage, IGHV mutation status, beta-2 microglobulin, creatinine clearance, B symptoms, and time from diagnosis were considered based on data availability and magnitude of imbalance between populations. To mitigate potential bias from the COVID-19 pandemic that overlapped in timing with SEQUOIA and not CLL14, additional analysis was conducted censoring for COVID-19 related deaths. Subgroup analysis was also conducted for IGHV mutation status. Pseudo-IPD for VenO were reconstructed from digitized Kaplan-Meier curves of progression-free survival per investigator (PFS-INV) and overall survival (OS). Sensitivity analyses were conducted in model scenarios of different matching variables.

Results: After applying the matching adjustment to align with the population characteristics of the VenO patients in CLL14 (N=216), the effective sample size (ESS) for zanubrutinib in SEQUOIA was 163. Zanubrutinib had longer PFS ($HR_{PFS-INV} = 0.66$ [95% CI: 0.44-0.97]; $p=0.0351$) and a trend for extended OS ($HR_{OS} = 0.89$ [95% CI: 0.55-1.46]; $p=0.6468$). Results were consistent after adjustment for COVID-19, $HR_{PFS-INV} = 0.58$ (95% CI: 0.38-0.88, $p=0.0095$) and $HR_{OS} = 0.74$ (95% CI: 0.43-1.25, $p=0.2587$), suggesting potential treatment benefit favoring zanubrutinib in terms of PFS-INV and OS, respectively. The efficacy of zanubrutinib vs VenO was also compared in the IGHV unmutated subgroup. After matching (SEQUOIA, ESS=93; CLL14, N=121), $HR_{PFS-INV}$ was 0.63 (95% CI: 0.39-1.03, $p=0.0652$) and 0.61 (95% CI: 0.37-0.99, $p=0.0475$) for the base and COVID-19 adjusted scenarios, respectively. Sensitivity analyses exploring the impact of using different sets of matching factors showed consistent results.

Conclusions: This unanchored MAIC investigated the relative efficacy of zanubrutinib vs VenO and suggested zanubrutinib had longer PFS and a trend for extended OS. Results should be interpreted with considerations of MAIC model assumptions and limitations. Further studies are needed to confirm these findings.